“Tafero EM 200/25 mg Pharmaceutical” has been added to your cart. View cart
£420.00
Additional information
| Active substance | Temozolomide |
|---|---|
| Water Retention | No significant impact |
| Hepatotoxicity | Low |
| Lab Test | CBC (Complete Blood Count) monitoring |
| Strength | 100mg |
| Also known as | TMZ, Methazolastone |
| Blood pressure | No direct effect |
| Trade name | Temodar, Temodal, Temcad |
| Storage conditions | Store at controlled room temperature, 20-25В°C (68-77В°F) |
| Chemical name | 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide |
| Formula | C6H6N6O2 |
| Substance class | Alkylating agent |
| Main action | Antineoplastic |
| Half-life | 1.8 hours |
| Dosage (medical) | Typically 150-200 mg/mВІ per day for 5 days every 28 days cycle |
| Dosage (sports) | Not applicable |
| Effects | Antitumor effect, crosses the blood-brain barrier |
| Side effects | Nausea, vomiting, constipation, loss of appetite, alopecia, headache, fatigue, neutropenia, thrombocytopenia |
| Use in sports | None |
| Manufacturer | Cipla Ltd. |
| Packing | 5 caps/bottle |
